chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache; fever; cold chills; body aches; arm pain; allergic reaction; diarrhea; fatigue; swollen lymph nodes; irritability; really swollen underarm with extreme pain on injection site arm that still has not resolved; really swollen underarm with extreme pain on injection site arm that still has not resolved; rash; difficulty breathing; This is a spontaneous report from a contactable consumer. This 34-year-old non-pregnant caucasian female consumer (patient) reported for herself that she received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on 04Mar2021 at 04: 30 PM on left arm as 2nd dose, single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The Historical vaccine of the patient included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on 11Feb2021 at 06:16 PM on left arm as 1st dose, single dose for COVID-19 immunization. It was reported that the patient did not receive any other vaccine in four weeks, she did not have covid prior vaccination and was not tested for covid post vaccination. On 04Mar2021 at 04:45 PM, the same day, fifteen minutes later the patient experienced headache, fever, cold chills, body aches, arm pain, allergic reaction, diarrhea, fatigue, swollen lymph nodes, irritability, really swollen underarm with extreme pain on injection site arm that still has not resolved, rash, difficulty breathing. It was unknown if patient received any treatment. The outcome of events was not recovered.   No follow-up attempts were possible. No further information was expected.
VF arrest 1 week after second Moderna vaccination. Successfully resuscitated, good neurologic outcome. Initial ejection fraction was low, 25%, currently improving. MRI with late gadolinium enhancement suggesting myocarditis. Troponin normal. Genetics panel without polymorphism predisposing to cardiomnyopathy.
Immunization site is red and hot to the touch. It is 3.5 x 3.5 area of redness and swelling. Looks like a bullseye. Pt. states it is painful. Grandmother said it started the day of the vaccination. As of today it is still red and hot.
Almost immediate soreness of arm that worsened ov over the next day. Low grade fever (99.1) at about 6 pm. Chills set in around 8 pm, followed by more widespread body aches. Fever 101.4 at 10 pm, 102 at 3 am, 102.4 at 6 am, 103 at 12:30 pm. Took extra strength Tylenol (2 caps) starting at 11 pm of first day and continued every 6 hours. Alternating extreme chills and sweating. Unable to sleep on the first night, no appetite/unable to eat for the first 24 hours at least.
Onset date for fever is 18MAY92, duration 7 days; 24MAY92 pt hot to touch, fussy & diarrhea; 25MAY92 mom took pt to hosp adm & dx w/viral meningitis; tx Ampicillin & Ceprotaximine; d/c 28MAY92 w/full recovery;
paralyzed; Initial information received on 22-Nov-2020 regarding an unsolicited valid serious case received from a social media via consumer or non-health care professional.  This case involves a patient of an unknown demographics who got paralyzed (paralysis), while patient received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.    On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [batch number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient got paralyzed (paralysis) unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.  Details of laboratory data not reported.  It was not reported if the patient received any corrective treatment.  At the time of reporting, the event outcome reported as unknown.  Batch number had been requested for suspect product for this case.; Sender's Comments: This poorly document case received from media concerns a patient with unknown demography who experienced paralysis after vaccination with INFLUENZA VACCINE (Flu shot), produced by unknown manufacturer. The time to onset is unknown. Moreover, patient's medical condition at time of vaccination, immune status and lab test ruling out alternate etiologies were not reported. Based upon the reported information the role of vaccine cannot be assessed.
Client received the vaccine on 1/8/21.  The arm was sore until 1/16/21 when it became red and tender to touch. Was still red and tender when she reported the reaction to the health department.
PATIENT RESIDES IN LONG TERM CARE FACILITY AND THEY REQUESTED A PFIZER COVID VACCINE FOR PATIENT, IT WAS ADMINISTERED AND UPON REPORTING TO IMMTRAC IT WAS DISCOVERED THAT PATIENT RECEIVED A JANSSEN VACCINE IN MARCH, PRIOR TO COMING TO THE FACILITY.  NO ADVERSE EFFECTS WERE EXPERIENCED BUT NEEDED TO REPORT THIS EVENT
Red itchy rash with bumps on chest and back. No associated fever or difficulty breathing. Self resolved in 2-3 days.
C/o severe neck pain, nausea, h/a. Afebrile post immunization 36 hrs.
ADMINISTRATION OF EXPIRED VACCINE; This spontaneous report received from a pharmacist concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A expiry: UNKNOWN) dose was not reported, administered on 30-JUN-2021 to Left Arm for prophylactic vaccination. No concomitant medications were reported.  On 30-JUN-2021, the subject experienced administration of expired vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of administration of expired vaccine was not reported. This report was non-serious.
On day following immunization, patient developed extremely sore arm. Then the next day, developed fever of 104 degrees, asthma worsened, and developed headache. Despite around the clock acetaminophen, fever remained above 100 degrees until 4th day after immunization.
Inappropriate schedule of vaccine administered; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034B21A and 047A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 14-May-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.   This case was linked to MOD-2022-446727 (Patient Link).
1 day p/vax had onset of urticarial rash;4 days p/had onset of multiple large joint arthritis (ankle, knees, hips, wrist) sx have persisted for 11 days so far;child has had intermittent fevers-picture is of serum sickness type rxn;Annual follow-up received on 11/08/00 provided no additional data.
Full body pain in all joints. Fever of 103.5 off and on for 3 full days with brief periods of break given OTC painkillers. Nausea and loss of fluids. Left armpit Lymph node extremely swollen and painful.
Initial report received from the patient on 05 June 2012. A 76-years-old female patient, whose medical history included hypertension and thyroid and concomitant medications were not reported, had received an intramuscular dose of FLUZONE HD (batch number not reported) on left deltoid, on 04 October 2011. On 04 October 2011, 1 hour after vaccination the patient had pain at the left deltoid. Pain had persisted and was moving up the arm and into the neck and the right arm was affected. Pain was persistent. Patient had physical therapy for 1 month with little change. Patient will be seeing an orthopedic MD. The event was not recovered at the time of reporting. Documents held by sender: none.
Extreme nausea, fatigue, weakness, and high heart rate started a few days after injection. Saw ER doc, primary doctor, cardiologist. She took a few weeks to recover and then proceeded to get similar nausea and fatigue week long episodes (1-2 most months) until April 2022.
1st dose Bexsero, 2nd dose Trumenba; This case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a 19-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis and MENINGOCOCCAL B VACCINE (TRUMENBA) for prophylaxis.   On 1st November 2021, the patient received the 1st dose of Bexsero and Bexsero Pre-Filled Syringe Device. On 6th December 2021, the patient received the 2nd dose of TRUMENBA. On an unknown date, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced interchange of vaccine products. On an unknown date, the outcome of the interchange of vaccine products was unknown.   This report is made without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: Pharmacist reported that, the patient was requesting a 2nd dose of Bexsero.  Problem was another pharmacy gave her Trumenba 06th December 2021 which led to interchange of vaccine products. The reporter did not consent to follow up. The Vaccine Administration Facility is the same as Primary Reporter.
Systemic: Dizziness / Lightheadness-Severe, Systemic: Tachycardia-Medium, Systemic: Visual Changes/Disturbances-Medium, Additional Details: EMS was called due to the patient feeling faint and tachycardia
on 12Aug2021 she had first symptoms of the Covid19 virus, and on 17Aug2021 she was tested positive with the virus; on 12Aug2021 she had first symptoms of the Covid19 virus, and on 17Aug2021 she was tested positive with the virus; This is a spontaneous report from a contactable consumer(patient). A 70-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported, Expiry date: unknown), via an unspecified route of administration, in Right Arm on 30Jul2021 (at the age of 69-years-old) as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 12Aug2021, the patient had experienced first symptoms of the covid19 virus, and on 17Aug2021 she was tested positive with the virus. She added that she was feeling better, and she wanted to know how to proceed with the 2nd dose. The events does not require a visit to emergency room and physician office. The patient underwent lab tests and procedures which included sars-cov-2 test positive: positive on 17Aug2021. The outcome of the events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
1-2 days after receiving shot in left deltoid, it became tender and red. Was seen in the ER and diagnosed with cellulitis requiring antibiotics and felt to be a reaction to the immunizatino.
Dizziness, Headache, Myalgia, Fever, arm soreness Narrative: Dizzy, myalgia, nausea, headache, arm soreness, fever 102;taking tylenol.
On Day 10 - Saturday (3/6/21) after my first vaccine shot of Moderna on (2/25/21) I started to experience itching & a red patch of skin on my left arm, same area as the injection site.  By Day 11 - Sunday (3/7/21) - there was a( 4"long x 2" wide) patch of red raised skin - again same area as the injection site that appeared on my left arm. It was very itchy and I put hydrocortisone on it to help with the itchiness. Today is Day 13 - Tuesday (3/9/21) - the redness of the area has definitely reduced a lot however it is still itchy on and off.  Other than this area, I feel totally fine and do not have any other side effects.  Calling my primary doctor tomorrow (3/10/21) to let them know about the side effects I have had.
Pt received Anthrax vaccine in rt arm around 1322. Pt stated later that evening he started noticing a little swelling and on 01/19/2018 he was limping and on 01/20/2018 he could not walk and called into work. Pt was seen at ER for swelling in rt leg and muscle spasms.
Extreme fatique, light fever, headachee, joint aches for about 24 hours.  Horrible pain in left shoulder between arm and neck with especially acute pain along collarbone near neck on the left side.  This was acute for about 24 hours then subsided to a much lower level and is almost gone 48 hours later.
Redness, mild swelling on (L) arm, warm to touch. Area measures 4 inch circum. No breathing problems noted. Gave 25mg BENADRYL at office exam and to take 25mg BENADRYL tonight and apply ice.
SHOULDER SORE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. The batch number was not-reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced shoulder sore. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from shoulder sore. This report was non-serious.
mild case of COVID-19 after the second shot.; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (mild case of COVID-19 after the second shot.) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (mild case of COVID-19 after the second shot.). At the time of the report, COVID-19 (mild case of COVID-19 after the second shot.) outcome was unknown.            Patient's weight was reported to be 130- units not specified.  No concomitant medications were reported. No treatment information was reported.  This case concerns a 69 year-old, female patient with no relevant medical history, who experienced the non serious unexpected AESI event of COVID-19. The event occurred on an unknown date after the second dose of Moderna COVID-19 vaccine. Information on first dose was not provided. The rechallenge was not applicable. The benefit-risk relationship of Moderna COVID-19 vaccine is not affected by this report.   This case was linked to MOD-2021-157249, MOD-2021-157264 (Patient Link).; Sender's Comments: This case concerns a 69 year-old, female patient with no relevant medical history, who experienced the non serious unexpected AESI event of COVID-19. The event occurred on an unknown date after the second dose of Moderna COVID-19 vaccine. Information on first dose was not provided. The rechallenge was not applicable. The benefit-risk relationship of Moderna COVID-19 vaccine is not affected by this report.
Large area of redness starting at site of Pneumococcal vaccine left posterior/lateral arm including anterior medial region. No pain- no fever - site of flu vaccine clear. No systemic complaints.
Shot given on Sunday. On Tuesday Rash, swelling in morning- evening- fever, chills- diarrhea. Wed. lost of energy- Shot given May 6th.
This spontaneous report was received from a Medical Assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 28-JAN-2016, the patient was vaccinated with a dose of improperly stored ROTATEQ orally, lot # L013188, expiration date: 02-NOV-2016 (exact dose was not reported). There were no concomitant medications provided. Administered doses of vaccines experienced the temperature excursion of 31.1 degrees Fahrenheit for 22 hours, 30 minutes. There were no adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Pt experienced severe rxns. Fever, hypotension, nausea & vomiting. Went to urgent care then office visit. Was out for 3 days.
On 25 February, 2021, the one week anniversary of my Covid shot (seven days later) I experience what I thought was a bug bite at approximately 5 PM. I noticed an itchy, dry, hard, spot which happened to be at the site of my first round of Moderna Covid immunization from the week before. The next morning, February 26, I noticed that it was far more itchy, and the spot was little bit blotchy. By that evening, the spot was swollen, super itchy, very firm, and hot to the touch.  I began researching this side effect on the internet and discovered that it is somewhat common with the Moderna vaccine.  I did not require an antihistamine nor a doctor?s visit.  The symptoms persisted throughout the next two days and then went away.  The symptoms did not cause any issues with day-to--day life, or work.
Felt sick; bedridden; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A patient (no qualifiers provided) received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MALAISE (non-serious), outcome "unknown", described as "Felt sick"; BEDRIDDEN (non-serious), outcome "unknown", described as "bedridden". Additional information: Felt sick after receiving Pfizer covid vaccine and was bedridden. Optional Information: Reported within required 24hr period. Event took place after use of product.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Had 3 Moderna shots (january, february, and the booster on 11/3/21).  After the 2nd shot, she had suffered from bilateral frozen shoulder.  She underwent PT for months and had completely recovered.  Immediately after the Booster shot, she suffered from frozen shoulder again, Is now unable to move R shoulder against gravity.
pt recv vax 5AUG97 & pt exp a severe case of chickenpox;
died; This is a spontaneous report from a contactable consumer reporting the same event under the same suspect product for three patients. This is one of three reports.   A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose number unknown, single for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient died on an unspecified date. It was unknown if an autopsy was performed.  The lot number for the vaccine (BNT162B2) was not provided and will be requested during follow-up.; Sender's Comments: Linked Report(s) : PFIZER INC-202101172210 Same reporter/product/event; different patient.; PFIZER INC-202101172301 Same reporter/product/event; different patient; Reported Cause(s) of Death: died
This is a spontaneous report from a contactable infectious disease pediatrician. This pediatrician reported similar events for five patients. This is the fifth of five reports. A patient (2, 3, or 4 years of age) (gender unknown) received a dose of PREVNAR 13 on an unspecified date. Relevant medical history, concomitant medications, and past drug events were not provided. On an unspecified date, the patient developed skin reaction and skin swelling. The pediatrician reported that one of their practices is seeing an increase in the amount of skin reactions to PREVNAR 13 in 2, 3, and 4-year-olds with the vaccine. The skin reactions are greater than 2.5 inches in diameter and they are seeing approximately five children a week with this type of swelling. The outcomes for the events were unknown.
Patient was admitted tO Hospital on 12/14/2021 for COVID pneumonia. This is considered a breakthrough case.
A physician reported that a female patient in her twenties received an injection of Flu Shield (2002-2003 formula) (influenza virus vaccine, trivalent, types a & b) on 11/1/02. The patient's mother contacted the physician's office to report the patient was experiencing arm pain that had started since she received the injection. She was seen on 11/18/02 and she was noted to have difficulty with range of motion. She could move her arm back and forth, but experienced pain moving it laterally. This is 1 of 3 patient's from this facility who developed pain at the injection site following administration of lot 4020029. The reporter noted that they suspected lot 4020029 was administered, but were not sure. This lot was the product in the office as of 11/29/02. See related HQ5549427NOV2002 and HQ5549927NOV2002.
Tinnitus in both ears. High pitch squeal. I would say 3 out of 10 for loudness.
Information has been received on 15-NOV-2018 regarding a case in litigation from a lawyer concerning a female patient of unknown age. There was no information regarding the patient's concurrent conditions, medical history or concomitant medications. The patient's healthcare provider, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On 20-MAY-2015, a healthcare provider at a pharmacy administered the ZOSTAVAX (lot number, expiration, dose and route unknown) to the patient. On 26-MAY-2015, the patient was treated by a healthcare provider at a physician's office for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events is unknown. The causality of the events is related. Additional information has been requested.
10/5/03: febrile and fussy; 10/7/03: rash on face and trunk. Seen by PCP. Dx: insect bite allergy. Tx: hydrocortisone cream. 10/8/03: Presented to ER. Afebrile, significant posterior cervical region nodes in the occipital node area, confluent erythematous maculopapular rash at hairline and on cheeks, small maculopapular 4-5mm diameter lesions on extremities. Dx: rubella, vaccine related. Tx: D/c hydrocortisone, Tylenol